CJC-1295 + Ipamorelin Blend out/DAC

The CJC-1295 + Ipamorelin blend with DAC (Drug Affinity Complex) is a synergistic combination designed to optimize growth hormone (GH) secretion through complementary pathways. CJC-1295 with DAC acts as a long-acting GHRH analog that provides a sustained baseline elevation of GH, while Ipamorelin, a selective ghrelin receptor agonist, induces acute, pulsatile spikes. Together, they promote improved body composition, increased lean muscle mass, faster post-workout recovery, and enhanced sleep quality. <br><br> The mechanism involves two distinct yet reinforcing actions. CJC-1295 with DAC is modified to bind to serum albumin, which significantly extends its half-life to several days, ensuring a steady, long-term stimulation of the pituitary's GHRH receptors. Ipamorelin, by contrast, binds directly to the ghrelin receptor (GHS-R1a) to trigger rapid GH release. This "pulse and baseline" approach mimics the body's natural physiological secretion patterns, which is considered more effective and better tolerated than constant synthetic GH administration. <br><br> Scientific evidence supports the efficacy of this combination in increasing serum IGF-1 levels, a primary biomarker for growth hormone activity. Research in endocrinology highlights that this multi-pathway stimulation provides a more robust response than either peptide used in isolation. While primarily studied for its impact on muscle-wasting, fat metabolism, and metabolic health, the stack is a standard focus in research regarding peptide-based endocrine optimization.